Additional file 17: of Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Table S9. PDX tumor growth during drug treatment (A) PDX-Bone tumor volume (mm3) and tumor weight (g), and (B) PDX-Bone mice body weight (g) in drug screening; (C) PDX-LN tumor volume (mm3) and tumor weight (g), and (D) PDX-LN mice body weight (g) in drug screening. (PDF 241 kb)